Osteopontin in diabetic nephropathy: signpost or road?
Defining the molecular pathogenesis of diabetic nephropathy remains a huge challenge to the medical research community. Recent studies of knockout mice have provided new insights into the role of osteopontin in the pathogenesis of diabetic nephropathy.
Eli Lilly and Company, Biotherapeutics Discovery Research, Lilly Corporate Center, Indianapolis, Indiana 46285, USA. jheuer@lilly.com
Josef G
JG
Heuer
Matthew D
MD
Breyer
D000419:Albuminuria / Q000188:drug therapy / Q000209:etiology; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D003928:Diabetic Nephropathies / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D051379:Mice; D053495:Osteopontin / Q000378:metabolism*; D045162:Thiazolidinediones / Q000627:therapeutic use
D045162:Thiazolidinediones; D053495:Osteopontin